Skip to content

Curis Stock Skyrockets After Positive Preliminary CA-4948 Data

Shares of biotechnology company Curis Inc (NASDAQ: CRIS) are surging premarket after the company reported positive preliminary data from its ongoing open-label, single-arm Phase 1 dose-escalation study of CA-4948.

The drug is used to treat patients with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndromes (MDS).

The primary objective of the study is to determine the maximum tolerated dose and a recommended Phase 2 dose for CA-4948. 

The study found that marrow blast reductions were observed in all six evaluable patients, with six of seven patients enrolled still on the study, two patients experienced a marrow complete response, and no dose-limiting toxicities were observed. 

“We are highly encouraged by the breadth of clinical activity with CA-4948 seen with this early data, especially as this study is both monotherapy and in a late line, relapsed/refractory population,” commented James Dentzer, President and CEO of Curis. 

CRIS

The company’s stock price has skyrocketed premarket, currently trading 201% higher at $4.34 per share, its highest level since 2018, after closing Monday’s session at $1.44.

PEOPLE WHO READ THIS ALSO VIEWED:

Sam Boughedda
Sam Boughedda
Team Member

Sam is a trader and lead stock market writer at AskTraders. After starting his career in the forex market, Sam now focuses on stocks, specifically consumer staples. 

Stay ahead of the markets

Sign up to our free Morning Markets email, every weekday before the open.